<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05622916</url>
  </required_header>
  <id_info>
    <org_study_id>1114222112</org_study_id>
    <nct_id>NCT05622916</nct_id>
  </id_info>
  <brief_title>Topical Ethanol Extract (Piper Crocatum) for Anogenital Warts</brief_title>
  <official_title>The Efficacy of Ethanol Extract of Red Betel Leaves (Piper Crocatum) as Topical Patient-Applied Therapy In Anogenital Warts The Study of Foxp3+ Treg, Tumor Growth Factor (TGF)-β1, and Interferon (IFN)-γ Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasanuddin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hasanuddin University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial aims to assess the efficacy of topical Piper crocatum in treating&#xD;
      Anogenital warts. It aims to answer&#xD;
&#xD;
        -  the clinical efficacy of treating anogenital warts&#xD;
&#xD;
        -  the expression of Foxp3+ regulatory T (Treg), TGF/Tumor Growth Factor -β1, and&#xD;
           IFN/interferon -γ of anogenital wart lesion Participants will be allocated into two&#xD;
           topical treatments, intervention and active comparator Trichloroacetic Acid (TCA) 90%.&#xD;
           The researchers assume that intervention is superior compared to TCA 90%&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design :&#xD;
&#xD;
      A randomized controlled trial&#xD;
&#xD;
      Population:&#xD;
&#xD;
      Diagnosed with Condyloma Acuminata (International Classification of Disease 10 code A.63.0)&#xD;
&#xD;
      Intervention period :&#xD;
&#xD;
      8 weeks of daily topical intervention with follow-up at week 12&#xD;
&#xD;
      Detailed formulation&#xD;
&#xD;
        1. Extraction of Piper crocatum with ethanol assisted in a microwave-assisted extraction&#xD;
           (MAE)&#xD;
&#xD;
        2. The dissolution and active substances are separated by evaporation using a rotary&#xD;
           evaporator to obtain the extract in the form of a thick solution&#xD;
&#xD;
        3. freeze-drying is performed to obtain a stable thick extract&#xD;
&#xD;
        4. preparation of ointment by adding formulation of ethanol extract of red betel leaves&#xD;
           with 50 mg of white vaseline to achieve 30% concentration&#xD;
&#xD;
      Settings:&#xD;
&#xD;
      Outpatient care at the designated hospital&#xD;
&#xD;
      Participants:&#xD;
&#xD;
      Consecutive recruitment&#xD;
&#xD;
      Sample Size Estimation:&#xD;
&#xD;
      Following the formula of two different means, with the indicator, as follows:&#xD;
&#xD;
        1. Type 1 error 5%&#xD;
&#xD;
        2. Power of Study 80%&#xD;
&#xD;
        3. Assuming the effect size of cohen d (in reducing the size of warts) is 0.5&#xD;
&#xD;
        4. equal allocation between two arms total sample: 100 participants&#xD;
&#xD;
      Proposed analysis:&#xD;
&#xD;
      Intention to treat (ITT) with sensitivity and subgroup analysis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2022</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>One group will receive the intervention, whereas the comparison group will receive standard care</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>participants will be blind from the allocation by mimicking the topical solution</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Size of wart</measure>
    <time_frame>Changes of wart size from baseline to week 12</time_frame>
    <description>the size of wart measured from the outermost edge of the warts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Foxp3+ regulatory T (Treg)</measure>
    <time_frame>change of Foxp3+ regulatory T (Treg) expression from baseline to week 8</time_frame>
    <description>the expression of Foxp3+ regulatory T (Treg) from the stained T cells in anogenital wart lesion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TGF-β1</measure>
    <time_frame>change of TGF-β1 expression from baseline to week 8</time_frame>
    <description>the expression of TGF-β1 from the stained cells in anogenital wart lesion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IFN-γ</measure>
    <time_frame>change of IFN-γ expression from baseline to week 8</time_frame>
    <description>the expression of IFN-γ from the stained cells in anogenital wart lesion</description>
  </primary_outcome>
  <other_outcome>
    <measure>Adverse reaction</measure>
    <time_frame>any adverse event from baseline to week 12</time_frame>
    <description>any records of adverse reaction including inflammation, irritation or other systemic adverse event</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Anogenital Wart</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily topical application (twice/day, in the morning and 30-60 minutes before bed at night) for 56 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparison</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weekly application (1x/week) by the physician for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Ethanol Extract (Piper crocatum)</intervention_name>
    <description>Topical ethanol extract of red betel leaves (Piper crocatum) 30% with the details of formulation on detailed description section</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Red Betel Leaves</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trichloroacetic Acid Topical</intervention_name>
    <description>Trichloroacetic acid topical 90%</description>
    <arm_group_label>Comparison</arm_group_label>
    <other_name>TCA 90</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women diagnosed with external anogenital warts&#xD;
&#xD;
          2. Clinical lesions of Anogenital Wart at least 3 lesions with a size of 1-5 cm&#xD;
&#xD;
          3. In patients with HIV, Cluster of Differentiation 4 (CD4)cell count &gt;350 cells/mm and&#xD;
             have been taking antiretroviral (ARV) drugs regularly for 3 months,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women&#xD;
&#xD;
          2. Lesions located in the external urethral orifice and vagina&#xD;
&#xD;
          3. Using systemic immunomodulators/immunosuppressants&#xD;
&#xD;
        The protocol treatment will be discontinued if patients&#xD;
&#xD;
        a. Withdraw their consent based on the patient's demand d. Severe adverse events occurred&#xD;
        or allergies to the components of the test product b. After undergoing clinical trials, the&#xD;
        patient experienced things that caused him/her to no longer meet the criteria set out in&#xD;
        this protocol. c. Subjects do not comply the established study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Idrianti Idrus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasanuddin University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wresti Indriatmi, MD. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indonesia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fransiscus Suyatna, MD. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indonesia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Idrianti Idrus, MD</last_name>
    <phone>+624118910174</phone>
    <email>rasiah.05@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wahidin Sudirohusodo General Hospital</name>
      <address>
        <city>Makassar</city>
        <state>South Sulawesi</state>
        <zip>76124</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>Agussalim Bukhari, MD, Ph.D.</last_name>
      <phone>+62 411 583333</phone>
      <email>fkunhas@med.unhas.ac.id</email>
    </contact>
    <investigator>
      <last_name>Idrianti Idrus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wresti Indriatmi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franciscus D Suyatna, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Sherrard J, Riddell L. Comparison of the effectiveness of commonly used clinic-based treatments for external genital warts. Int J STD AIDS. 2007 Jun;18(6):365-8. doi: 10.1258/095646207781024711.</citation>
    <PMID>17609022</PMID>
  </reference>
  <reference>
    <citation>Gilson R, Nugent D, Werner RN, Ballesteros J, Ross J. 2019 IUSTI-Europe guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol. 2020 Aug;34(8):1644-1653. doi: 10.1111/jdv.16522.</citation>
    <PMID>32735077</PMID>
  </reference>
  <reference>
    <citation>Sazwi NN, Nalina T, Abdul Rahim ZH. Antioxidant and cytoprotective activities of Piper betle, Areca catechu, Uncaria gambir and betel quid with and without calcium hydroxide. BMC Complement Altern Med. 2013 Dec 11;13:351. doi: 10.1186/1472-6882-13-351.</citation>
    <PMID>24330738</PMID>
  </reference>
  <reference>
    <citation>Pharm T, Hartini YS, Wahyuono S, Widyarini S, Yuswanto A. Hartini et al In vivo Immunomodulatory Effect and Histopathological Features of Mouse Liver and Kidney Treated with Neolignans Isolated from Red Betel (Piper crocatum Ruiz &amp; Pav) Leaf. Tropical Journal of Pharmaceutical Research. 2014;13:1609-1614. doi:10.4314/tjpr.v13i10.6</citation>
  </reference>
  <reference>
    <citation>Bonin CM, Padovani CTJ, da Costa IP, Avila LS, Ferreira AMT, Fernandes CES, Dos Santos AR, Tozetti IA. Detection of regulatory T cell phenotypic markers and cytokines in patients with human papillomavirus infection. J Med Virol. 2019 Feb;91(2):317-325. doi: 10.1002/jmv.25312. Epub 2018 Sep 24.</citation>
    <PMID>30192406</PMID>
  </reference>
  <reference>
    <citation>Xu Y, Zhu KJ, Zhu N, Jiang DH, Chen XZ, Cheng H. Expression of Foxp3+CD4+CD25+ regulatory T cells and Th1/Th2, Tc1/Tc2 profiles in the peripheral blood of patients with condyloma acuminatum. Clin Exp Dermatol. 2009 Mar;34(2):229-35. doi: 10.1111/j.1365-2230.2008.03001.x. Epub 2008 Dec 2.</citation>
    <PMID>19077104</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasanuddin University</investigator_affiliation>
    <investigator_full_name>Bumi Herman</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <keyword>Anogenital Wart</keyword>
  <keyword>Trichloroacetic</keyword>
  <keyword>Piper crocatum</keyword>
  <keyword>Clinical Efficacy</keyword>
  <keyword>Inflammatory Marker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>de-identified data will be shared for specific purpose, including article review</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

